By Landon Gray
A growing specialist contract organization, hVIVO—a subsidiary of Open Orphan plc—has been tapped by Cocrystal Pharma to conduct a phase 2a clinical trial of its novel broad-spectrum, orally administered antiviral candidate, CC-42344.
Housed in hVIVO’s state-of-the-art facility in the United Kingdom, the trial has been designed to evaluate safety, viral and clinical measures of CC-42344 orally administered to patients who are infected with influenza A. The trial